Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
- 20 August 1996
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 93 (17) , 9235-9240
- https://doi.org/10.1073/pnas.93.17.9235
Abstract
The dopamine hypothesis of schizophrenia proposes that hyperactivity of dopaminergic transmission is associated with this illness, but direct observation of abnormalities of dopamine function in schizophrenia has remained elusive. We used a newly developed single photon emission computerized tomography method to measure amphetamine-induced dopamine release in the striatum of fifteen patients with schizophrenia and fifteen healthy controls. Amphetamine-induced dopamine release was estimated by the amphetamine-induced reduction in dopamine D2 receptor availability, measured as the binding potential of the specific D2 receptor radiotracer [123I] (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl]benzamide ([123I]IBZM). The amphetamine-induced decrease in [123I]IBZM binding potential was significantly greater in the schizophrenic group (-19.5 +/- 4.1%) compared with the control group (-7.6 +/- 2.1%). In the schizophrenic group, elevated amphetamine effect on [123I]IBZM binding potential was associated with emergence or worsening of positive psychotic symptoms. This result suggests that psychotic symptoms elicited in this experimental setting in schizophrenic patients are associated with exaggerated stimulation of dopaminergic transmission. Such an observation would be compatible with an abnormal responsiveness of dopaminergic neurons in schizophrenia.Keywords
This publication has 48 references indexed in Scilit:
- Imaging endogenous dopamine competition with [11C]raclopride in the human brainSynapse, 1994
- D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic PatientsThe British Journal of Psychiatry, 1994
- Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primatesSynapse, 1992
- Effects of endogenous dopamine on measures of [18F]N‐methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboonsSynapse, 1991
- Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamideJournal of Medicinal Chemistry, 1988
- Dopamine receptors and the dopamine hypothesis of schizophreniaSynapse, 1987
- Regional in vivo binding of [3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptorsEuropean Journal of Pharmacology, 1981
- Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivoJournal of Pharmacy and Pharmacology, 1978
- Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in BrainScience, 1977